bevacizumab
Pronunciation: beh-vah-SIZ-oo-mab
Monoclonal antibody targeting VEGF used as anti-angiogenic therapy for recurrent glioblastoma.
Full Definition
Bevacizumab is a humanized monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), reducing tumor blood vessel formation. In neurosurgical oncology, it is primarily used for treating recurrent glioblastoma multiforme when standard therapies have failed. The drug can cause unique side effects including wound healing complications and intracranial hemorrhage, making timing relative to surgical procedures critical. Editorial staff should note the drug requires careful capitalization and is often referenced in treatment protocols and adverse event reports.
Usage
Usage note: Always lowercase unless beginning a sentence. Trade name Avastin should be capitalized.
In Context
- "The patient received bevacizumab therapy following tumor recurrence at six months post-resection." — Treatment protocol document
- "Bevacizumab-related wound healing complications delayed the planned re-operation by three weeks." — Case report